No Increased Risk of Symptomatic Intracerebral Hemorrhage After Thrombolysis in Patients With European Cooperative Acute Stroke Study (ECASS) Exclusion Criteria

被引:33
|
作者
Cronin, Carolyn A. [1 ]
Shah, Nikeith [1 ]
Morovati, Tanya [2 ]
Hermann, Lisa D. [3 ]
Sheth, Kevin N. [1 ]
机构
[1] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA
[2] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA
[3] Vanderbilt Univ, Dept Neurol, Nashville, TN USA
关键词
acute stroke; exclusion criteria; thrombolysis; TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; TIME;
D O I
10.1161/STROKEAHA.112.656587
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-The European Cooperative Acute Stroke Study (ECASS) III trial used additional exclusion criteria not present in current guidelines for thrombolytic therapy in the United States (age >80 years; National Institutes of Health Stroke Scale >25, combination of previous stroke and diabetes, aggressive measures required to control blood pressure [intravenous infusion], and oral anticoagulant treatment). We tested the hypothesis that thrombolysis is not safe in patients with 1 of the additional exclusion criteria. Methods-All patients treated with intravenous tissue-type plasminogen activator for acute stroke at our center between June 2006 and June 2010 were identified (n=191), and stratified based on presence of each of the exclusion criteria. Primary outcomes were rate of symptomatic intracerebral hemorrhage and in-hospital mortality. Additionally, patients with and without symptomatic intracerebral hemorrhage were analyzed for differences in baseline characteristics. Results-No exclusion criterion was associated with increased risk of symptomatic intracerebral hemorrhage. Symptomatic intracerebral hemorrhage was associated with atrial fibrillation (5 of 9 [55%], versus 35 of 182 [19.2%]; P=0.021), larger final infarct volume (mean 173 mL(3) versus 42 mL(3); P=0.0002), and elevated glucose (mean 166 mg/dL versus 127 mg/dL; P=0.038). There was higher mortality in patients >80 years (5 of 31 [16%] versus 6 of 160 [4%]; P=0.0186) and those with National Institutes of Health Stroke Scale >25 (2 of 5 [40%] versus 7 of 159 [4.4%]; P=0.025). Conclusions-In our cohort, none of the more stringent exclusion criteria from ECASS III were associated with increased risk of symptomatic intracerebral hemorrhage. Prospective randomized studies are needed clarify the safety and efficacy of tissue-type plasminogen activator in these patients through all treatment time windows. (Stroke. 2012;43:1684-1686.)
引用
收藏
页码:1684 / 1686
页数:3
相关论文
共 50 条
  • [1] Leukoaraiosis as a marker of increased risk of symptomatic intracerebral hemorrhage after thrombolysis in acute stroke
    Hoelig, S
    Humpich, MC
    Yan, B
    Fiehler, J
    Kucinski, T
    Rosso, C
    Deltour, S
    Samson, Y
    Liebeskind, DS
    Saver, JL
    Berkefeld, J
    Neumann-Haefelin, T
    STROKE, 2006, 37 (02) : 707 - 707
  • [2] Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke
    Neumann-Haefelin, Tobias
    Hoelig, Silke
    Berkefeld, Joachim
    Fiehler, Jens
    Gass, Achim
    Humpich, Marek
    Kastrup, Andreas
    Kucinski, Thomas
    Lecei, Olivera
    Liebeskind, David S.
    Rother, Joachim
    Rosso, Charlotte
    Samson, Yves
    Saver, Jeffrey L.
    Yan, Bernhard
    STROKE, 2006, 37 (10) : 2463 - 2466
  • [3] GLYCOSILATED HEMOGLOBIN A1 AND RISK OF SYMPTOMATIC INTRACEREBRAL HEMORRHAGE AFTER THROMBOLYSIS IN ACUTE ISCHEMIC STROKE
    Dorado, L.
    Lopez-Cancio, E.
    Crespo, A. M.
    Garcia-Esperon, C.
    Munoz, L.
    Hernandez-Perez, M.
    Perez de la Ossa, N.
    Gomis, M.
    Millan, M.
    Davalos, A.
    CEREBROVASCULAR DISEASES, 2014, 37 : 77 - 77
  • [4] Symptomatic intracerebral and systemic hemorrhage after stroke thrombolysis in patients taking ticagrelor
    Lo, Kar Yan
    Biby, Sharon
    Sethi, Pramod
    Campbell, Bruce C. V.
    INTERNATIONAL JOURNAL OF STROKE, 2016, 11 (06) : NP71 - NP72
  • [5] The impact of blood pressure variation on mortality and symptomatic intracerebral hemorrhage in acute stroke patients after thrombolysis
    Kotruchin, Praew
    Kliangsa-Ard, Harirak
    Imoun, Supap
    Kongbunkiat, Kannikar
    Mitsungnern, Thapanawong
    BLOOD PRESSURE MONITORING, 2022, 27 (03) : 192 - 198
  • [6] Glucose Control and Risk of Symptomatic Intracerebral Hemorrhage Following Thrombolysis for Acute Ischemic Stroke
    Southerland, Andrew M.
    Mayer, Stephan A.
    Chiota-McCollum, Nicole A.
    Bolte, Ashley C.
    Pauls, Qi
    Pettigrew, L. Creed
    Bleck, Thomas P.
    Conaway, Mark
    Johnston, Karen C.
    NEUROLOGY, 2024, 102 (09) : e209323
  • [7] Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke
    Palumbo, V.
    Boulanger, J. M.
    Hill, M. D.
    Inzitari, D.
    Buchan, A. M.
    NEUROLOGY, 2007, 68 (13) : 1020 - 1024
  • [8] ECASS III: the third European Cooperative Acute Stroke Study
    Kaste, M
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, : 41 - 42
  • [9] Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis
    Strbian, D.
    Sairanen, T.
    Meretoja, A.
    Pitkaniemi, J.
    Putaala, J.
    Salonen, O.
    Silvennoinen, H.
    Kaste, M.
    Tatlisumak, T.
    NEUROLOGY, 2011, 77 (04) : 341 - 348
  • [10] INTRAVENOUS THROMBOLYSIS WITH RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE HEMISPHERIC STROKE - THE EUROPEAN COOPERATIVE ACUTE STROKE STUDY (ECASS)
    HACKE, W
    KASTE, M
    FIESCHI, C
    TONI, D
    LESAFFRE, E
    VONKUMMER, R
    BOYSEN, G
    BLUHMKI, E
    HOXTER, G
    MAHAGNE, MH
    HENNERICI, M
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13): : 1017 - 1025